Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study.

Trial Profile

Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary) ; Cefalexin; Ceftriaxone
  • Indications Bacterial infections; Liver abscess
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 10 May 2011 Preliminary results presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.
    • 27 Dec 2010 Planned end date changed from 1 Apr 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top